Bixiye
P33-19 New Medical, Medical Drug and Behavioral Health Policy Management Updates for Commercial & Medicare Advantage Lines of Business
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2019
Dukumentiyadda & Foomamka Natiijooyinka
Soo bandhiga 2081 - 2090 ee natiijooyinka 3613
Bixiye
P35-19 Appeals Policy for no Prior Authorization Effective June 3, 2019
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 01, 2019
Bixiye
QP30-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Hereditary transthyretin-mediated (hATTR) Amyloidosis Neuropathy
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP33-19 SmartChoice Program for Fully Insured Commercial Products
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP32-19 Pharmacy Benefit Exclusion for Glyrx-PF, Libtayo, Lumoxiti, Onpattro, Poteligeo, and Xerava
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP34-19 Pharmacy Benefit Exclusion for Antineoplastic and Adjunctive Therapies
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP31-19 Change to Outpatient Therapies Prior Authorization Requirements for Medicare Advantage Subscribers
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP29-19 Pharmacy Benefit Update – New Drug-Related Prior Authorization with Quantity Limit Criteria: Arikayce
Taariikhda uu dhaqangalayo Barnaamijka: Mar 27, 2019
Bixiye
QP23-19 Reminder Payment Policy Auditing System
Taariikhda uu dhaqangalayo Barnaamijka: Mar 13, 2019
Bixiye
QP28-19 Interest Paid on Clean Claims
Taariikhda uu dhaqangalayo Barnaamijka: Mar 13, 2019